Terns Pharmaceuticals reported a net loss of $23.9 million for the first quarter of 2025, compared to a net loss of $22.4 million for the same period in the prior year. The company ended the quarter with $334.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028. The company highlighted progress in its clinical programs, with dose expansion initiated for TERN-701 in CML and good enrollment in the FALCON trial for TERN-601 in obesity, with key data readouts expected in Q4 2025.

Terns Pharmaceuticals reported a net loss of $21.8 million for the fourth quarter of 2024, with cash, cash equivalents, and marketable securities totaling $358.2 million, providing a runway into 2028. The company made significant clinical progress with TERN-701 and TERN-601, with key trial initiations and data readouts expected in 2025.

Terns Pharmaceuticals reported its Q3 2024 financial results, highlighting positive topline results from the Phase 1 study of TERN-601 and a successful equity raise of $172.7 million that extends the company's cash runway into 2028. The company's cash, cash equivalents, and marketable securities totaled $372.8 million as of September 30, 2024.

Terns Pharmaceuticals reported its second quarter 2024 financial results, highlighting upcoming milestones for its TERN-601 and TERN-701 programs. The company's cash, cash equivalents, and marketable securities totaled $225.3 million, expected to fund operations into 2026.

Terns Pharmaceuticals reported a net loss of $22.4 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $240.7 million as of March 31, 2024, expected to provide runway into 2026. Key milestones include ongoing Phase 1 trials for TERN-701 and TERN-601 with data readouts expected in the second half of 2024.

Terns Pharmaceuticals reported a net loss of $21.0 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $263.4 million as of December 31, 2023, which is expected to fund operations into 2026. The company is advancing its clinical programs for TERN-601 and TERN-701.

Terns Pharmaceuticals reported a net loss of $29.8 million for the quarter ended September 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $266.6 million, expected to fund operations into 2026.

Terns Pharmaceuticals reported its Q2 2023 financial results, featuring positive data from the Phase 2a DUET trial of TERN-501 in NASH and updates on its TERN-701 and TERN-601 programs. The company's cash, cash equivalents, and marketable securities are expected to provide runway into 2026.

Terns Pharmaceuticals reported a net loss of $21.5 million for the first quarter ended March 31, 2023. The company's cash, cash equivalents, and marketable securities totaled $297.5 million as of March 31, 2023, expected to provide runway into 2026.

Terns Pharmaceuticals reported its Q4 and full year 2022 financial results. The company's cash and cash equivalents were $283.1 million as of December 31, 2022, expected to provide runway into 2026. Key leadership appointments were announced in oncology R&D and business development.

Terns Pharmaceuticals reported its Q3 2022 financial results, highlighting progress in their clinical programs. They plan to initiate a U.S. clinical trial for TERN-701 in CML and expect top-line data from the Phase 2a DUET trial of TERN-501 in NASH in the second half of 2023. IND-enabling activities for TERN-601 remain on track. The company's cash and equivalents of $187 million are expected to provide a runway into 2025.

Terns Pharmaceuticals reported a net loss of $13.9 million for the second quarter ended June 30, 2022. As of June 30, 2022, cash, cash equivalents and marketable securities were $139.8 million.

Terns Pharmaceuticals reported its Q1 2022 financial results, highlighting the advancement of its pipeline, including the opening of the combination therapy IND for NASH and the initiation of key IND-enabling activities in the GLP-1 program for obesity, along with a clinical trial for TERN-701 in chronic myeloid leukemia by their partner in China. The company's cash runway extends into 2025, supporting key clinical trial readouts across three indications.

Terns Pharmaceuticals reported its Q4 and full year 2021 financial results, highlighting the expected top-line data readout from the TERN-201 clinical trial in NASH in March 2022, and the planned initiation of the Terns' first NASH trial of TERN-501 alone and in combination with TERN-101 in the first half of 2022.

Terns Pharmaceuticals reported a net loss of $11.8 million for the third quarter ended September 30, 2021. The company's cash and equivalents were $177.2 million as of September 30, 2021, providing a cash runway into 2024.

Terns Pharmaceuticals reported a net loss of $10.7 million for the second quarter ended June 30, 2021. As of June 30, 2021, cash, cash equivalents and marketable securities were $185.1 million. Top-line data from the TERN-501 Phase 1 trial is expected in 4Q 2021, and data from Part 1 of the TERN-201 AVIATION Trial is expected in 1H 2022.

Terns Pharmaceuticals reported a net loss of $13.3 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $195.6 million as of March 31, 2021, which is expected to fund operations into 2024.

Terns Pharmaceuticals reported its Q4 and full-year 2020 financial results, highlighting a cash position of $74.9 million and the completion of an upsized initial public offering in February 2021, which raised approximately $147 million. The company anticipates data readouts for its clinical programs and the initiation of a combination clinical trial of TERN-101 and TERN-501.